Symposia: Myeloproliferative Syndromes: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Clinical Research, Chronic Myeloid Malignancies, Diseases, Therapies, Immunotherapy, Myeloid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Clinical Research, Chronic Myeloid Malignancies, Diseases, Therapies, Immunotherapy, Myeloid Malignancies
Monday, December 11, 2023: 10:30 AM-12:00 PM
Ballroom 20CD
(San Diego Convention Center)
Moderators:
Lynda Foltz, MD, University of British Columbia
and
Steffen Koschmieder, University Hospital of Aachen
Disclosures:
Foltz: Amgen: Other: Spouse is an employee and holds equity and stock options. ; Incyte: Consultancy, Research Funding; PharmaEssentia: Research Funding; CTI Biopharma: Research Funding; BMS: Honoraria, Research Funding; Constellation: Research Funding; GSK: Consultancy, Research Funding; Novartis: Consultancy, Honoraria. Koschmieder: Geron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; AOP Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Incyte: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Ariad: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Meyers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Squibb: Consultancy, Honoraria; CTI Biopharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; RWTH Aachen University: Patents & Royalties: patent issued for a BET inhibitor; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Sierra Oncology: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Karthos: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Imago Bioscience: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; Geron, Janssen, AOP Pharma, Novartis: Research Funding; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, Bristol Myers Squibb, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Protagonist, MPN Hub, Bedrock, PharmaEssentia: Consultancy; Novartis, BMS/Celgene, Pfizer, Incyte, AOP Orphan, GSK, AbbVie, MPN Hub, Bedrock, iOMEDICO: Honoraria; Alexion, Novartis, Bristol Myers Squibb, Incyte, AOP Pharma, CTI BioPharma, Pfizer, Celgene, Janssen, Geron, Roche, AbbVie, GSK, Sierra Oncology, Kartos, Imago Biosciences, MSD, iOMEDICO: Other: Travel/accommodation support; RWTH Aachen University: Patents & Royalties: BET inhibitor; Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI BioPharma, Roche, Bayer, GSK, Sierra Oncology, AbbVie, Protagonist, PharmaEssentia: Other: Advisory board; Protagonist: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support; GSK: Membership on an entity's Board of Directors or advisory committees, Other: travel/accommodation support.
This session explores treatment of classic and rare myeloproliferative neoplasms (MPN) with both established and novel therapies. Hydroxyurea and pegylated interferon are common first line treatments for MPN, each with potential advantages and disadvantages. The DALIAH study reports long term outcomes of MPN patients randomized to hydroxyurea vs pegylated interferon, providing additional information regarding molecular response rates and adverse events to assist in treatment selection. But do these results apply to younger patients? Separately, a large cohort of young adults < 25 years old with essential thrombocythemia (ET) and polycythemia vera (PV) is followed for impact of cytoreduction on long term clinical outcomes including thrombosis and progression to myelofibrosis. Novel therapies include hepcidin mimetic rusfertide in PV and the LSD-1 inhibitor bomedemstat in ET. In mastocytosis, the KIT inhibitor bezuclastinib shows efficacy and safety in patients with indolent mastocytosis. In myeloid neoplasms with eosinophilia, a custom NGS panel is used to explore the molecular landscape in patients negative for tyrosine kinase fusion genes, identifying recurrent JAK/STAT mutations associated with response to JAK inhibitors.
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH